PMID- 37191911
OWN - NLM
STAT- MEDLINE
DCOM- 20230706
LR  - 20230718
IS  - 1558-822X (Electronic)
IS  - 1558-8211 (Linking)
VI  - 18
IP  - 4
DP  - 2023 Aug
TI  - A Pragmatic Approach to Managing Long-Term Adverse Effects in Chronic Myeloid 
      Leukemia Treatment.
PG  - 98-104
LID - 10.1007/s11899-023-00698-4 [doi]
AB  - PURPOSE OF REVIEW: Long-term outcomes have significantly improved with treatment 
      of chronic myeloid leukemia. With proper treatment, most patients will achieve 
      similar survival rates compared to an age-matched population. Treatment-free 
      remission is not attainable for over half of patients and chronic treatment 
      carries with it unique challenges. We provide a pragmatic approach to the 
      monitoring and management of chronic adverse effects (AEs). RECENT FINDINGS: In 
      the presence of severe or intolerable AEs, switching tyrosine kinase inhibitors 
      (TKIs) is reasonable but is not without risk. Dose reductions can be attempted 
      when response is stable to reduce AE intensity. More frequent molecular 
      monitoring with any change is essential. Treatment strategies must adapt to the 
      personalized treatment goal of each patient. Long-term survival remains good even 
      when response is less than a complete molecular response. Consider risks of new 
      AEs when changing therapy and evaluate for dose reductions when appropriate.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Lucero, Josephine Anne
AU  - Lucero JA
AUID- ORCID: 0000-0003-4681-3536
AD  - Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 
      University Health Network, 610 University Avenue, Toronto, ON, M5G2M9, Canada. 
      Josephine.Lucero@uhn.ca.
FAU - Lipton, Jeffrey H
AU  - Lipton JH
AD  - Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 
      University Health Network, 610 University Avenue, Toronto, ON, M5G2M9, Canada.
AD  - Division of Hematology, University of Toronto, Toronto, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230516
PL  - United States
TA  - Curr Hematol Malig Rep
JT  - Current hematologic malignancy reports
JID - 101262565
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
MH  - Humans
MH  - Protein Kinase Inhibitors/adverse effects
MH  - *Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
MH  - Remission Induction
MH  - *Drug-Related Side Effects and Adverse Reactions
OTO - NOTNLM
OT  - Adverse effects
OT  - Chronic myeloid leukemia
OT  - TKI long-term effects
EDAT- 2023/05/16 13:10
MHDA- 2023/07/06 06:42
CRDT- 2023/05/16 11:16
PHST- 2023/04/20 00:00 [accepted]
PHST- 2023/07/06 06:42 [medline]
PHST- 2023/05/16 13:10 [pubmed]
PHST- 2023/05/16 11:16 [entrez]
AID - 10.1007/s11899-023-00698-4 [pii]
AID - 10.1007/s11899-023-00698-4 [doi]
PST - ppublish
SO  - Curr Hematol Malig Rep. 2023 Aug;18(4):98-104. doi: 10.1007/s11899-023-00698-4. 
      Epub 2023 May 16.